Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry, & Status of FDA Orange Book Exclusivities covering 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17alpha)

Client Email

Product

19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17alpha)
U.S. EXCLUSIVITIES

PharmaCompass Sponsored Ads

Contact Supplier

Gonane Norethisterone acetate

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17alpha)

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

22 API Suppliers, 12 USDMF, 4 CEP/COS, 2 JDMF, 3 EU WC, 6 NDC API, 12 Listed Suppliers, $ API Reference Price

22 API Suppliers
12 USDMF
4 CEP/COS
2 JDMF
3 EU WC
6 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

25 Drugs in Development

25 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Imports

FINISHED DOSAGE FORMULATIONS

168 FDF Dossiers, 119 FDA Orange Book, 39 Europe, 7 Canada, 3 Listed Dossiers

168 FDF Dossiers
119 FDA Orange Book
39 Europe
7 Canada
3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL-28 - 0.02MG;1MG, TABLET;ORAL-21 - 0.03MG;1.5MG, TABLET;ORAL-21 - 0.03MG;1.5MG, TABLET;ORAL-21 - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 11.25MG/VIAL,N/A;N/A,5MG, INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 3.75MG/VIAL,N/A;N/A,5MG, CAPSULE;ORAL - 0.02MG;1MG, TABLET, CHEWABLE, TABLET;ORAL - 0.01MG,0.01MG,N/A;1MG,N/A,N/A, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.14MG/24HR, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.25MG/24HR, TABLET;ORAL - 0.5MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 1MG;0.5MG, TABLET;ORAL - 0.0025MG;0.5MG, TABLET;ORAL - 0.005MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.01MG,0.01MG;1MG,N/A

TABLET;ORAL-28 - 0.02MG;1MG
TABLET;ORAL-21 - 0.03MG;1.5MG
TABLET;ORAL-21 - 0.03MG;1.5MG
TABLET;ORAL-21 - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 11.25MG/VIAL,N/A;N/A,5MG
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL - 3.75MG/VIAL,N/A;N/A,5MG
CAPSULE;ORAL - 0.02MG;1MG
TABLET, CHEWABLE, TABLET;ORAL - 0.01MG,0.01MG,N/A;1MG,N/A,N/A
FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.14MG/24HR
FILM, EXTENDED RELEASE;TRANSDERMAL - 0.05MG/24HR;0.25MG/24HR
TABLET;ORAL - 0.5MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 1MG;0.5MG
TABLET;ORAL - 0.0025MG;0.5MG
TABLET;ORAL - 0.005MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 0.01MG,0.01MG;1MG,N/A

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 5 SPI Pharma, 4 DKSH, 2 Jai Radhe Sales, 6 Boai NKY Pharmaceuticals Ltd, 13 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 4 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 19 BASF, 2 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 11 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 38 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 4 Novo Excipients, 3 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 23 Roquette, 13 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 5 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

85 Fillers, Diluents & Binders, 56 Coating Systems & Additives, 41 Direct Compression, 34 Disintegrants & Superdisintegrants, 29 Controlled & Modified Release, 27 Granulation, 26 Solubilizers, 23 Thickeners and Stabilizers, 21 Lubricants & Glidants, 19 Co-Processed Excipients, 17 Taste Masking, 16 Film Formers & Plasticizers, 14 Parenteral, 10 Emulsifying Agents, 9 Topical, 8 API Stability Enhancers, 7 Chewable & Orodispersible Aids, 6 Rheology Modifiers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

85 Fillers, Diluents & Binders
56 Coating Systems & Additives
41 Direct Compression
34 Disintegrants & Superdisintegrants
29 Controlled & Modified Release
27 Granulation
26 Solubilizers
23 Thickeners and Stabilizers
21 Lubricants & Glidants
19 Co-Processed Excipients
17 Taste Masking
16 Film Formers & Plasticizers
14 Parenteral
10 Emulsifying Agents
9 Topical
8 API Stability Enhancers
7 Chewable & Orodispersible Aids
6 Rheology Modifiers
5 Empty Capsules
5 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 47 NEWS #PharmaBuzz

3 DATA COMPILATION #PharmaFlow
47 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 40 Finished Drug Prices, 9 Annual Reports

2 US Medicaid Prescriptions
40 Finished Drug Prices
9 Annual Reports

MARKET PLACE

7 APIs

7 APIs

PATENTS & EXCLUSIVITIES

9 US Patents, 4 US Exclusivities

9 US Patents
4 US Exclusivities

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 3 Others

2 EDQM
1 USP
3 Others

$ API Ref.Price (USD/KG) : 7,465 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

4 All

01 4SUMITOMO PHARMA

filter Product Reset all filters

4 All

01 4ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

filter Exclusivity Expiration Date Reset all filters

4 All

01 12024-05-26

02 12025-08-05

03 12025-12-18

04 12026-01-27

filter Exclusivity Code Reset all filters

4 All

01 1I-898

02 1M-289

03 1NCE

04 1NP

Coral Drugs Norethisterone Acetate

US Patents
US Exclusivities

Product Main Page

SUMITOMO PHARMA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

I-898

Exclusivity Expiration Date

2025-08-05

Application Number

214846

Product Number

1

Exclusivity Details

01

SUMITOMO PHARMA

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

AAPS 2024

Not Confirmed

SUMITOMO PHARMA

Japan

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Exclusivity Code : I-898

Exclusivity Expiration Date : 2025-08-05

Application Number : 214846

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

SUMITOMO PHARMA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

M-289

Exclusivity Expiration Date

2026-01-27

Application Number

214846

Product Number

1

Exclusivity Details

02

SUMITOMO PHARMA

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

AAPS 2024

Not Confirmed

SUMITOMO PHARMA

Japan

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Exclusivity Code : M-289

Exclusivity Expiration Date : 2026-01-27

Application Number : 214846

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

SUMITOMO PHARMA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2024-05-26

Application Number

214846

Product Number

1

Exclusivity Details

03

SUMITOMO PHARMA

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

AAPS 2024

Not Confirmed

SUMITOMO PHARMA

Japan

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Exclusivity Code : NP

Exclusivity Expiration Date : 2024-05-26

Application Number : 214846

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

SUMITOMO PHARMA

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NCE

Exclusivity Expiration Date

2025-12-18

Application Number

214846

Product Number

1

Exclusivity Details

04

SUMITOMO PHARMA

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

AAPS 2024

Not Confirmed

SUMITOMO PHARMA

Japan

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Exclusivity Code : NCE

Exclusivity Expiration Date : 2025-12-18

Application Number : 214846

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?